Author

N. Temperton

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:host-pathogen & immune response· 6 Organism:mouse· 5 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

G. Carnell· 3 shared M. Mayora-Neto· 2 shared S. Scott· 2 shared A. A. Compton· 1 shared A. Amini· 1 shared A. Chan· 1 shared A. Dijokaite-Guraliuc· 1 shared A. Huckriede· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 9 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

G. Carnell

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Alternative splicing expands the antiviral IFITM repertoire in Chinese horseshoe bats

N. Mak, D. Zhang, X. Li, K. Rahman, S. A. K. Datta, J. Taylor, J. Liu, Z. Shi, N. Temperton, A. T. Irving, A. A. Compton, R. D. Sloan

The paper identifies alternative splicing of IFITM genes in Chinese horseshoe bats, producing two isoforms with differential antiviral activities against influenza and coronaviruses.

bioRxiv · Dec 4, 2023 · PreprintMicrobiology

Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum

A. Tuekprakhon, J. Huo, R. Nutalai, A. Dijokaite-Guraliuc, D. Zhou, H. M. Ginn, M. Sekvaraj, C. Liu, A. J. Mentzer, P. Supasa, H. M. E. Duyvesteyn, R. Das, D. Skelly, T. G. Ritter, A. Amini, , G. R. Screaton

This study shows that BA.4 and BA.5 variants are more resistant to neutralization by vaccine and BA.1 immune sera compared to BA.1 and BA.2.

bioRxiv · May 21, 2022 · PreprintMicrobiology

Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected Patients

D. Cantoni, M. Mayora-Neto, N. Thakur, A. M. Elrefaey, J. Newman, S. Vishwanath, A. Nadesalingam, A. Chan, P. Smith, J. Castillo-Olivares, H. Baxendale, B. Charleston, J. Heeney, D. Bailey, N. Temperton

This study shows that convalescent sera from SARS-CoV-2 infected patients efficiently neutralize RaTG13, a close coronavirus relative, more effectively than SARS-CoV-2 itself.

bioRxiv · Aug 17, 2021Microbiology

Reservoir host studies of Lloviu virus: first isolation, sequencing and serology in Schreiber's bats in Europe

G. Kemenesi, G. E. Toth, M. Mayora-Neto, S. Scott, N. Temperton, E. Wright, E. Muhlberger, A. J. Hume, B. Zana, S. A. Boldogh, T. Gorfol, P. Estok, Z. Lanszki, B. A. Somogyi, A. Nagy, , F. Jakab

This study isolates and characterizes Lloviu virus from Schreiber's bats in Europe, showing its ability to infect human and monkey cells and suggesting potential spillover risks.

bioRxiv · Aug 10, 2021Microbiology

The bat influenza H17N10 can be neutralized by broadly-neutralizing monoclonal antibodies and its neuraminidase can facilitate viral egress.

G. Carnell, E. Giotis, K. Grehan, F. Ferrara, S. Mather, E. Molesti, S. Scott, A. Pessi, K. Lacek, N. Temperton

This paper shows that bat influenza H17N10 can be neutralized by human antibodies and its neuraminidase N10 aids viral release without using sialic acid as a receptor.

bioRxiv · Jan 12, 2019 · PreprintMicrobiology

The MHC class-II HLA-DR receptor mediates bat influenza A-like H17N10 virus entry into mammalian cells

E. S. Giotis, G. Carnell, E. F. Young, S. Ghanny, P. Soteropoulos, W. S. Barclay, M. A. Skinner, N. Temperton

This study identifies HLA-DR as a receptor for bat influenza A-like H17N10 virus entry into mammalian cells, revealing a novel mechanism distinct from classical influenza A viruses.

bioRxiv · Jan 4, 2019Microbiology

Cross-protective immune responses induced by sequential influenza virus infection and by sequential vaccination with inactivated influenza vaccines

W. Dong, Y. Bhide, F. Sicca, T. Meijerhof, K. Guilfoyle, O. G. Engelhardt, L. Boon, C. A.M. de Haan, G. Carnell, N. Temperton, J. de Vries-Idema, D. J. Kelvin, A. Huckriede

This study shows that sequential vaccination with inactivated influenza vaccines can reduce pandemic virus infection severity, while subunit vaccines cannot, through cross-reactive antibodies and CD8+ T cells.

bioRxiv · May 31, 2018Microbiology